Keywords: bi, regains, pramipexole, product, portfolio, germany, boehringer
BI regains pramipexole product portfolio
Article | 25 October 2004
Germany's Boehringer Ingelheim has reported the return of the Parkinson's disease drug pramipexole (Mirapex/Mirapexin) to the company's portfolio of ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- US FDA advisory panel backs approval of Merck & Co's suvorexant, but only at lower doses
- Alchemia and Merck Serono collaborate on HA-Irinotecan with Erbitux
- AstraZeneca's naloxegol meets endpoints; EMA validates Gilead's sofosbuvir MAA
- Boehringer Ingelheim gets FDA warning letter on cGMP failures
- Italy's pharma market slump set to continue, warns GlobalData
